CLN6’s luminal tail-mediated functional interference between CLN6 mutants as a novel pathomechanism for the neuronal ceroid lipofuscinoses

Yuki SHIRO, Arisa YAMASHITA, Kana WATANABE, and Tetsuo YAMAZAKI
Department of Molecular Cell Biology and Medicine, Graduate School of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan

(Received 5 April 2021; and accepted 25 May 2021)

ABSTRACT
CLN6 (Ceroid Lipofuscinosis, Neuronal, 6) is a 311-amino acid protein spanning the endoplasmic reticulum membrane. Mutations in CLN6 are linked to CLN6 disease, a hereditary neurodegenerative disorder categorized into the neuronal ceroid lipofuscinoses. CLN6 disease is an autosomal recessive disorder and individuals affected with this disease have two identical (homozygous) or two distinct (compound heterozygous) CLN6 mutant alleles. Little has been known about CLN6’s physiological roles and the disease mechanism. We recently found that CLN6 prevents protein aggregate formation, pointing to impaired CLN6’s anti-aggregate activity as a cause for the disease. To comprehensively understand the pathomechanism, overall anti-aggregate activity derived from two different CLN6 mutants needs to be investigated, considering patients compound heterozygous for CLN6 alleles. We focused on mutant combinations involving the S132CfsX18 (132fsX) prematurely terminated protein, produced from the most frequent mutation in CLN6. The 132fsX mutant nullified anti-aggregate activity of the P299L CLN6 missense mutant but not of wild-type CLN6. Wild-type CLN6’s resistance to the 132fsX mutant was abolished by replacement of amino acids 297–301, including Pro297 and Pro299, with five alanine residues. Given that removal of CLN6’s C-terminal fifteen amino acids 297–311 (luminal tail) did not affect the resistance, we suggested that CLN6’s luminal tail, when unleashed from Pro297/299-mediated conformational constraints, is improperly positioned by the 132fsX mutant, thereby blocking the induction of anti-aggregate activity. We here reveal a novel mechanism for dissipating CLN6 mutants’ residual functions, providing an explanation for the compound heterozygosity-driven pathogenesis.

INTRODUCTION
CLN6 (Ceroid Lipofuscinosis, Neuronal, 6) is an endoplasmic reticulum (ER) protein and contains an N-terminal cytoplasmic domain, seven putative transmembrane domains, and a luminal C-terminus (Gao et al. 2002; Wheeler et al. 2002). Mutations in CLN6 are linked to the development of CLN6 disease, one type of the neuronal ceroid lipofuscinoses (NCLs), a group of hereditary neurodegenerative disorders comprised of thirteen distinct types (Kollmann et al. 2013; Palmer et al. 2013; Warrier et al. 2013; Cárcel-Trullols et al. 2015; Mole et al. 2019; Butz et al. 2020; Nelvagal et al. 2020). CLN6 disease is characterized by seizures, motor difficulties, visual failure, and a shortened life-span, and is heterogeneous clinically and genetically, implying that CLN6’s functionality is differentially impaired among patients (Alroy et al. 2011). CLN6’s functions have been poorly understood, thereby making it difficult to assess the impacts of mutations in CLN6.

We previously showed that tethering the small
heat shock protein αB-crystallin (αBC), which otherwise is widely distributed throughout the cytoplasm, to the ER membrane suppresses aggregation of the myopathy-causing R120G αBC missense mutant (Yamamoto et al. 2014), highly prone to aggregate even when transfected into cell lines (Vicart et al. 1998). Subsequently, we isolated CLN6 as a binder to the ER-tethered αBC and revealed that CLN6 can prevent the R120G αBC mutant from aggregating. These findings indicated that the R120G αBC mutant serves as a model protein in determining the anti-aggregate activity of CLN6 and its mutants. Indeed, we demonstrated by employing the R120G αBC mutant that CLN6’s anti-aggregate activity is compromised to various extents depending on which pathogenic mutation is introduced into CLN6 (Yamashita et al. 2017, 2020). The finding led us to propose that the difference in functionality among CLN6 mutants can be assessed based on their anti-aggregate activity. We have so far analyzed anti-aggregate activity in a cell line transfected with a single CLN6 mutant. The activity detected is most likely to correlate with that in a patient homozygous for the corresponding CLN6 mutant. On the other hand, in order to predict what happens in patients compound heterozygous for CLN6 mutants, but not the activity of each mutant, is required to be investigated.

In this study, we show that the anti-aggregate activity of one CLN6 mutant can be nullified by another mutant, pointing to functional interference between CLN6 mutants as the pathomechanisms operating in patients with CLN6 compound heterozygosity. Our findings have provided novel insight into the molecular basis of clinical and genetic heterogeneity of CLN6 disease.

MATERIALS AND METHODS

Expression vectors. The construction of pEGFP-N1-R120G αBC mutant (R120G αBC), pcDNA4/Myc-wild-type CLN6 (WT) and DNA4/Myc-R106PψsX26 CLN6 mutant (106ψsX) was described previously (Yamamoto et al. 2014; Yamashita et al. 2017, 2020). The DNA fragment corresponding to the S132CψsX18, D173EψsX33, F239PψsX29 and A243PψsX26 CLN6 frameshift mutants (hereafter referred to as 132ψsX, 173ψsX, 239ψsX and 243ψsX, respectively) were generated by sequential PCRs. The first-step PCR was conducted using PrimerSTAR Mutagenesis Basal Kit (TAKARA Bio) with the pcDNA4/Myc-wild-type CLN6 as a template in combination with primers, named “Fwd” and “Rev” (Supporting Table 1). The PCR products were used as a template for the second-step PCR with following primers sets, “132ψsX”, “173ψsX”, “239ψsX” and “243ψsX” (Supporting Table 2). Other Myc-tagged CLN6 mutants were generated with the pcDNA4/Myc-wild-type CLN6 as a template in combination with primers described in Supporting Table 3. All the constructs were subjected to DNA sequencing. To generate pFLAG-CMV-5.1-wild-type CLN6 (CLN6-FLAG) and pFLAG-CMV-5.1-P299L CLN6 mutant (P299L-FLAG), pcDNA4/Myc-wild-type CLN6 or pcDNA4/myc-P299L CLN6 mutant were digested with HindIII/EcoRI and cloned in frame into the HindIII/EcoRI-digested pFLAG-CMV-5.1 (Sigma-Aldrich).

Cell culture and transfection. HeLa cells were maintained in Dulbecco’s Modified Eagle Medium (nacalai tesque, Japan) supplemented with 10% fetal bovine serum at 37°C in a humidified cell culture incubator with 5% CO₂. For transfection experiments in 24-well plates, 1.5 × 10⁵ HeLa cells were seeded per well in 0.5 mL of the cell growth medium 20 h before transfection. The cells in each well were transfected with 1.2 μL of Polyethylenimine (PEI) “Max” (Polysciences) mixed with 0.4 μg of single or multiple expression plasmids, where 0.2 μg each of two plasmids or 0.13 μg each of three plasmids were used. The transfection efficiency under these conditions was approximately 80% in all experiments.

Immunoblotting assays. At 16 h post-transfection, HeLa cells were lysed with 1 × Laemmli sample buffer (0.5 mM Tris-HCl (pH 6.8), 1.25% SDS, 12.5% glycerol, 1.25% 2-mercaptoethanol and 2.5% bromophenol blue), then centrifuged at 14,800 rpm for 5 min. The supernatant was collected, heated at 95°C for 1 min, resolved by SDS-PAGE, and electrotransferred onto polyvinylidene difluoride membranes. Then, the membranes were incubated with antibodies against Actin (1 : 200 diluted; Santa Cruz Biotechnology, C-2, sc-8432) or Myc (1 : 200 diluted; Santa Cruz Biotechnology, 9E10, sc-40) or FLAG (0.5 mM Tris-HCl (pH 6.8), 1.25% SDS, 12.5% glycerol, 1.25% 2-mercaptoethanol and 2.5% bromophenol blue), then centrifuged at 14,800 rpm for 5 min. The supernatant was collected, heated at 95°C for 1 min, resolved by SDS-PAGE, and electrotransferred onto polyvinylidene difluoride membranes. Then, the membranes were incubated with antibodies against Actin (1 : 200 diluted; Santa Cruz Biotechnology, C-2, sc-8432) or Myc (1 : 200 diluted; Santa Cruz Biotechnology, 9E10, sc-40) or FLAG (1 : 4500 diluted; Cell Signaling Technology) for 8 h at 4°C. Afterwards, the membranes were incubated for 20 min with horseradish peroxidase (HRP)-conjugated antibodies (1 : 8000 diluted; rabbit anti-mouse IgG, DAKO or 1 : 8000 diluted; goat anti-rabbit IgG, DAKO). HRP on the membrane was detected using the ECL Advance luminescence solution (GE Healthcare Life Science) according to the manufacturer’s instruction.
Interference of CLN6 mutants

**Immunoprecipitation assays.** HeLa cells were solubilized in lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1% Nonidet P40 (NP-40), and protease inhibitor cocktail). Anti-FLAG antibody (Cell Signaling Technology) was added in the lysates and incubated for 15 min, and then protein A-Sepharose (GE Healthcare Life Sciences) was added and mixed by rotation for 15 min. Afterwards, protein A-Sepharose was collected and washed three times with lysis buffer. Finally, 2 × Laemmli sample buffer was added in the samples and heated at 95°C for 1 min.

**Measurement of aggregate positivity.** To visualize the EGFP-tagged R120G αBC missense mutant, a fluorescence microscope IX-51 (Olympus, Japan) with 20×/0.40 NA dry objective was used. At 16 h post-transfection, HeLa cells expressing EGFP-tagged R120G αBC mutants were illuminated with the mercury light (U-LH100HGAPQ). EGFP images were captured with a digital camera WRAYCAM-SR300 (WRAYMER, Japan) and WraySpect (WRAYMER, Japan). WRAYCAM-SR300 was used through 0.35×c-mount lens. The EGFP-tagged R120G αBC mutant was observed as speckles of various size or as a diffuse signal widely distributed throughout the cytoplasm. A cell with speckle(s) was counted as an aggregate-positive cell, regardless of how large a speckle is and of how many speckles are found in the cell. The proportion of the aggregate-positive cells to the EGFP-positive cells was calculated and is shown as “Cells with aggregates (%).” At least 800 cells were analyzed for each condition in every assay.

**Statistical analysis.** All data are expressed as means ± S.E.M. The data was accumulated under each condition from at least five independent experiments. For parametric all-pairs multiple comparisons in all figures, Tukey-test was used.

**RESULTS**

The 132fsX truncated mutant was unable to prevent the R120G αBC mutant’s aggregation

CLN6 disease is heterogeneous clinically and genetically (Cannelli et al. 2009; Chin et al. 2019). In order to investigate if the disease heterogeneity is associated with dysregulation of CLN6’s anti-aggregate activity, we focused on the 132fsX prematurely terminated protein (Fig. 1A), which arises from a 2-bp deletion (c.395–396delCT), the most common mutation in CLN6, and corresponds to amino acids 1–131 of CLN6 followed by an irrelevant 18-amino acid stretch (Wheeler et al. 2002). Not only patients homozygous for the 132fsX mutant but also those compound heterozygous for this mutant have been described, among whom clinical manifestations are not consistent (Wheeler et al. 2002; Cannelli et al. 2009). Structurally, the 132fsX mutant lacks CLN6’s third loop and beyond, the region required for CLN6’s anti-aggregate activity (Yamashita et al. 2020). Collectively, the 132fsX mutant was expected to serve as an ideal tool with which to further explore the relationship between the disease heterogeneity and the reduction in CLN6’s anti-aggregate activity. We first determined if the 132fsX mutant suppresses aggregation of the R120G disease-causing αBC mutant, a model protein highly prone to aggregate. When transfected into HeLa cells, the EGFP-tagged R120G αBC mutant was visualized as a diffuse signal widely distributed throughout the cytoplasm (the mutant spared from aggregation) or as intracellular speckles (the aggregated mutant) (Yamamoto et al. 2014). Based on microscopic images, we calculated the proportion of aggregate-positive cells to EGFP-positive cells. Transfection of Myc-tagged wild-type CLN6 into HeLa cells lowered aggregate positivity by ~15% compared with controls employing the insertless vector expressing Myc alone (Fig. 1B–D). In contrast, the percentage of aggregate-positive cells was not significantly affected upon transfection of the Myc-tagged 132fsX mutant, suggesting that the mutant lacks anti-aggregate activity.

The 132fsX mutant nullified anti-aggregate activity of coexisting CLN6 mutants

The 132fsX mutant-involving compound heterozygosity has been reported in four patients (Cannelli et al. 2009). Two of them have the 239fsX prematurely terminated protein, which arises from a 4-bp deletion (c.715–718delTTCG) and corresponds to amino acids 1–238 of CLN6 followed by an irrelevant 29-amino acid stretch (Cannelli et al. 2009) and the 132fsX truncated mutant, and the other two the P299L CLN6 missense mutant (Sharp et al. 2003) and the 132fsX truncated mutant (Fig. 2A). Meanwhile, the 106fsX truncated mutant, which corresponds to amino acids 1–105 of CLN6 followed by an irrelevant 26-amino acid stretch (Wheeler et al. 2002), has been found only in homozygous patients (Fig. 2A). The 1-bp insertion (c.316insC) producing the 1-bp insertion (c.316insC) producing the 106fsX prematurely terminated protein is identical to that in the nclf mouse, a naturally-occurring mouse model of CLN6 disease (Bronson et al. 1998; Gao et al. 2002; Wheeler et al. 2002; Kurze et al. 2019).
We previously demonstrated that the 106fsX truncated mutant is unable to prevent the R120G αBC mutant from aggregating (Yamashita et al. 2020). In contrast with the 106fsX mutant, both the 239fsX and the P299L mutants inhibited the R120G αBC mutant’s aggregation comparably to wild-type CLN6 (Fig. 2B, C). The finding prompted us to assess if their anti-aggregate activity is affected by simultaneous expression of the 132fsX mutant. Aggregate positivity in HeLa cells transfected with the 239fsX and the 132fsX mutants was ~15% higher than that in the cells transfected with the 239fsX mutant alone (Fig. 2D). Likewise, the P299L mutant’s anti-aggregate activity was attenuated upon coexpression of the 132fsX mutant. Both the 239fsX and the P299L mutants were similarly disabled by the 106fsX truncated mutant. Given that wild-type CLN6’s activity toward the R120G αBC mutant was not negatively impacted by the 106fsX or the 132fsX mutant (Fig. 2D), we suggested that these mutants
Interference of CLN6 mutants

Mutants are prematurely terminated proteins; the former arises from a 1-bp deletion (c.519delT) and corresponds to amino acids 1–172 of CLN6 followed by an irrelevant 33-amino acid stretch, and the latter arises from a 1-bp deletion (c.727delG) and corresponds to amino acids 1–242 of CLN6 followed by an irrelevant 26-amino acid stretch. We thus investigated if these three truncated mutants differentially affect the P299L mutant’s anti-aggregate activity. The P299L mutant, when expressed alone, suppressed the R120G αBC mutant’s aggregate lacking CLN6’s third loop and beyond specifically counteract the coexisting CLN6 mutants.

The P299L mutant was selectively vulnerable to the 132fsX truncated mutant

In CLN6 disease patients, the 239fsX mutant has been described solely in combination with the 132fsX mutant. On the other hand, the P299L mutant has been found together with the 132fsX, the 173fsX, or the 243fsX mutant (Fig. 3A) (Cannelli et al. 2009; Kousi et al. 2012). Both the 173fsX and the 243fsX mutants are prematurely terminated proteins; the former arises from a 1-bp deletion (c.519delT) and corresponds to amino acids 1–172 of CLN6 followed by an irrelevant 33-amino acid stretch, and the latter arises from a 1-bp deletion (c.727delG) and corresponds to amino acids 1–242 of CLN6 followed by an irrelevant 26-amino acid stretch. We thus investigated if these three truncated mutants differentially affect the P299L mutant’s anti-aggregate activity. The P299L mutant, when expressed alone, suppressed the R120G αBC mutation’s aggre-
Integrity of CLN6’s amino acids 297–301 was required to resist the 132fsX mutant. The importance of proline in protein structure is widely accepted (DeTar et al. 1977). Given that mutations of Pro297 and Pro299 in CLN6 have been described in patients (Sharp et al. 2003; Kousi et al. 2012), these proline residues would serve to ensure CLN6’s structural integrity and consequently contribute to protection against the 132fsX mutant. We thus explored this idea by replacing amino acids 297–301 in CLN6 with five alanine residues (Fig. 4A; 5A1). The 5A1 mutant, when expressed alone, suppressed the R120G αBC mutant’s aggregation (Fig. 4B, C). Its anti-aggregate activity, however, was attenuated, as shown by aggregate positivity of ~25% (Fig. 3B; Ev). The positivity was elevated by coexpression of the 106fsX or the 132fsX mutants, but not of the 173fsX or the 243fsX mutant. We thus reasoned that the P299L mutant is compromised only by truncated mutants that can physically interact with the P299L mutant. This was not the case in fact. Coimmunoprecipitation assays showed that every single truncated mutant employed here binds not only to the P299L mutant but also to wild-type CLN6 (Fig. 3C). Taken together, we suggested that the P299L mutant is disabled preferentially by truncated mutants lacking CLN6’s third loop and beyond.

Integrity of CLN6’s amino acids 297–301 was required to resist the 132fsX mutant. The importance of proline in protein structure is widely accepted (DeTar et al. 1977). Given that mutations of Pro297 and Pro299 in CLN6 have been described in patients (Sharp et al. 2003; Kousi et al. 2012), these proline residues would serve to ensure CLN6’s structural integrity and consequently contribute to protection against the 132fsX mutant. We thus explored this idea by replacing amino acids 297–301 in CLN6 with five alanine residues (Fig. 4A; 5A1). The 5A1 mutant, when expressed alone, suppressed the R120G αBC mutant’s aggregation (Fig. 4B, C). Its anti-aggregate activity, however, was attenuated,
The mutational analysis noted above led us to hypothesize that when unleashed from structural constraints imposed by the amino acids 297–301, CLN6’s luminal tail (amino acids 297–311) is improperly positioned by the 132fsX mutant, thereby causing a failure to exert anti-aggregate activity. We thus tested our hypothesis using a CLN6 mutant lacking amino acids 297–311 (Fig. 5A; P297X). The P297X mutant not only displayed anti-aggregate activity comparably to wild-type CLN6 but also was resistant to the coexisting 132fsX mutant (Fig. 5B–D), indicating that the amino acids 297–301 are key to CLN6’s resistance to the 132fsX mutant.

Removal of CLN6’s luminal tail resulted in insensitivity to the 132fsX mutant

The mutational analysis noted above led us to hypothesize that when unleashed from structural constraints imposed by the amino acids 297–301, CLN6’s luminal tail (amino acids 297–311) is improperly positioned by the 132fsX mutant, thereby causing a failure to exert anti-aggregate activity. We thus tested our hypothesis using a CLN6 mutant lacking amino acids 297–311 (Fig. 5A; P297X). The P297X mutant not only displayed anti-aggregate activity comparably to wild-type CLN6 but also was resistant to the coexisting 132fsX mutant (Fig. 5B–D), arguing for our hypothesis. Collectively, we suggested that a loss of a tight structural control over CLN6’s luminal tail underlies the vulnerability to the 132fsX mutant.
DISCUSSION

Both the P299L and the 5A1 mutants, when expressed alone, prevented aggregation of the R120G αBC mutant. These mutants’ anti-aggregate activity was, however, offset by the simultaneously expressed 132fsX mutant. Meanwhile, wild-type CLN6 was not affected by the 132fsX mutant, indicating that integrity of CLN6’s amino acids 297–301 is vital to resisting the 132fsX mutant-driven interference. The importance of this five-amino-acid stretch is also supported by genetic findings in patients. Within CLN6’s C-terminal thirty amino acids (282–311), which follow the seventh transmembrane domain and face the ER lumen, six mutations have been found. All except one accumulate within amino acids 297–301: Pro297Thr, Pro297LeufsX, Glu298Lys, Pro299Leu, and Trp300Arg (Sharp et al. 2003; Teixeira et al. 2003; Arsov et al. 2011; Kousi et al. 2012; Sun et al. 2018). It should be noted that mutations at both Pro297 and Pro299 have been found in patients. The critical role that proline plays for protein structure has been well known (DeTar et al. 1977; Jing et al. 1998; Newbold et al. 2001). In contrast, the extent to which amino acid residues other than proline contribute to protein structure is not generalized. We expected that what the amino acids 297–301 provide is a structural basis for CLN6’s functionality, which would be established chiefly by Pro297 and Pro299. Indeed, the P299L and the 5A1 mutants, when coexpressed with the 132fsX, became unable to display their intrinsic anti-aggregate activity, arguing for our idea. Furthermore, the P297X mutant, which lacks CLN6’s luminal tail (amino acids 297–311), exerted its anti-aggregate activity either with or without the 132fsX.

Fig. 5 Removal of CLN6’s luminal tail resulted in insensitivity to the 132fsX mutant. (A) Schematic representation of wild-type CLN6 (WT) and the P297X mutant. (B) Immunoblot analysis performed as in Fig. 1(B). (C and D) Cells were transfected with the indicated combinations and amounts of expression vectors, and analyzed as in Fig. 1(C, D). The data represent mean ± SEM of six independent experiments. * P < 0.05.
Interference of CLN6 mutants

Interference of CLN6 mutants

the 132fsX mutant, shield the P299L mutant’s region responsible for its anti-aggregate activity from access of its luminal tail. Meanwhile, the 239fsX mutant was compromised by the coexpressed 132fsX mutant despite the lack of the stretch of amino acids corresponding to CLN6’s luminal tail. It might be that an exquisite arrangement of seven transmembrane segments is indispensable for CLN6’s structural stability. Considering that Phe239 is predicted to be in the middle of CLN6’s sixth transmembrane segment (Sharp et al. 2003), the 239fsX mutant would be less rigid relative to wild-type CLN6. In consequence, the 123fsX mutant is likely to disturb the 239fsX mutant’s structure, thereby nullifying its anti-aggregate activity. Recently, a homozygous mutation in cat CLN6 has been reported, where a guanine to adenine change (c.668G>A) creates a termination codon at Trp 223 (pTrp223Ter) (Katz et al. 2020). Like human CLN6, cat CLN6 is also predict-
ed to have seven transmembrane domains based on TMHMM, a membrane protein topology prediction program (http://www.cbs.dtu.dk/services/TMHMM/) and the Trp223 is situated in the fifth transmembrane domain (Supporting Fig. 1). A cat homozygous for the c.668G>A mutation displayed clinical signs characteristic of the neuronal ceroidal lipofusci-
noses, revealing that the protein product pTrp223Ter is a loss-of-function CLN6 mutant. Given that the 239fsX human CLN6 mutant is prematurely terminated in the sixth transmembrane domain, a perturbation in CLN6 transmembrane domains is likely to affect the entire structure of CLN6 and in turn to impair its functionality.

The third loop, predicted to face the ER lumen and also referred to as the second luminal loop, of CLN6 has been associated with ER-to-Golgi trafficking of a spectrum of lysosomal enzymes (Bajaj et al. 2020). We previously demonstrated the requirement for the third loop in CLN6’s anti-aggregate activity (Yamashita et al. 2020). Based on the dysfunctionality of the pTrp223Ter cat CLN6 mutant (Katz et al. 2020) and the vulnerability of the 239fsX human CLN6 mutant to the 132fsX truncat-
ed mutant, the presence of the third loop itself is necessary but not sufficient for the full-fledged activity of CLN6. It might be that a premature termi-
nation within CLN6’s transmembrane domains results in the disruption of an exquisite spatial arrangement of each domain, thereby altering the third loop’s structure.

We have demonstrated that the 132fsX mutant offsets the 239fsX and the P299L mutants’ suppressive effect on the R120G αBC mutant’s aggregation, and that neither the 173fsX nor the 243fsX mutant exhibits such compromising activity, proposing that clinical outcomes of patients compound heterozygous for the 132fsX mutant and either the 239fsX or the P299L mutant are attributable to the loss of anti-aggregate activity. On the other hand, symp-
toms of patients with either homozygosity for the P299L mutant or compound heterozygosity for the P299L mutant and the 173fsX or the 243fsX mutant might be explained by CLN6’s functional defects unrelated to its anti-aggregate activity. Alternatively, the clinical manifestations of this group of patients would be ascribed to aggregation of CLN6’s physiological targets. A caveat is that what we have determined so far is anti-aggregate activity toward the R120G αBC mutant, a model protein, but not that toward CLN6’s physiological target proteins. Therefore, the prevention of the R120G αBC mutant’s aggrega-
tion validated in HeLa cells transfected with the P299L mutant alone or together with the 173fsX or the 243fsX mutant, does not necessarily mean that every single CLN6’s physiological target is safeguarded against aggregation-inducing insults in patients harboring the P299L mutant alone or to-
gether with the 173fsX or the 243fsX mutant. We hence expect that the spectrum of CLN6’s physiological targets remaining functional is different from patient to patient depending on which mutant or combination of CLN6 mutants each patient has, thereby giving rise to the symptom disparity. Patients with compound heterozygosity for the P299L and the 173fsX mutants have been reported to present with visual impairment, a characteristic feature of late infan-
tile-onset CLN6 disease, whereas those with homozygosity for the P299L mutant not (Cannelli et al. 2009), arguing for our idea.

Here we propose that the functional interference between coexisting CLN6 mutants is implicated in the development of CLN6 disease. Our findings pro-
vide novel insight into pathogenic mechanisms operating in patients with compound heterozygosity for CLN6 mutants.

Acknowledgements

This work was supported by Japan Society for the
Y. Shiro et al.

Promotion of Science (JSPS) KAKENHI Grant Numbers JP18K07045 (T. Y.) and JP16J09784 (A. Y.), and the Tokushima Shimbun Science Grant (Y. S.).

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

REFERENCES

Aloy J, Braulke T, Cismondi IA, Cooper JD, Creegan D, et al. (2011) CLN6. in: Neuronal Cereoid Lipofuscinoses (Batten Disease) (ed. by Mole SE et al.) pp159–175, Oxford University Press.

Arsov T, Smith KR, Damiano J, Franceschetti S, Canafoglia L, et al. (2011) Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in cln6. Am J Hum Genet 88, 566–573.

Bajal J, Sharma J, di Ronza A, Zhang P, Eblimit A, et al. (2020) A CLN6–CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer. J Clin Invest 140, 4118–4132.

Bronson RT, Donahue LR, Johnson KR, Tanner A, Lane PW, et al. (1998) Neuronal ceroid lipofuscinosis (ncll), a new disorder of the mouse linked to chromosome 9. Am J Med Genet 77, 289–297.

Butz ES, Chandrachud U, Mole SE and Cotman SL (2020) Moving towards a new era of genomics in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta – Mol Basis Dis 1866, 165571.

Cannelli N, Garavaglia B, Simonati A, Aiello C, Barzaghi C, et al. (2009) Variant late infantile ceroid lipofuscinoses associated with novel mutations in CLN6. Biochim Biophys Res Commun 379, 892–897.

Cárcelet-Trullols J, Kovács AD and Pearce DA (2015) Cell biology of the NCL proteins: What they do and don’t do. Biochim Biophys Acta – Mol Basis Dis 1852, 2242–2255.

Chin JJ, Behnam B, Davids M, Sharma P, Zein WM, et al. (2019) Novel mutations in CLN6 cause late-infantile neuronal ceroid lipofuscinosis without visual impairment in two unrelated patients. Mol Genet Metab 126, 188–195.

DeTar DLF and Luthra NP (1977) Conformations of Proline. J Am Chem Soc 99, 1232–1244.

Gao H, Boustany RMM, Espinola JA, Cotman SL, Srinidhi L, et al. (2009) Mutations in a novel CLN6-encoded transmembrane protein cause variant late infantile neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet 70, 324–335.

Heine C, Quitsch A, Storch S, Martin Y, Lonka L, et al. (2007) Topology and endoplasmic reticulum retention signals of the lysosomal storage disease-related membrane protein CLN6. Mol Memb Biol 24, 74–87.

Jing Pl, Dogovski C and Pittard AJ (1998) Functional consequences of changing proline residues in the phenylalanine-specific perampe of Escherichia coli. J Bacteriol 180, 5515–5519.

Katz ML, Buckley RM, Biegen V, O’Brien DP, Johnson GC, et al. (2020) Neuronal ceroid lipofuscinoses in a domestic cat associated with a DNA sequence variant that creates a premature stop codon in CLN6. G3 Genes, Genomes, Genet 10, 2741–2751.

Kollmann K, Uusi-Rauta K, Scifo E, Tyynenli J, Jalanko A, et al. (2013) Cell biology and function of neuronal ceroid lipofuscinoses-related proteins. Biochim Biophys Acta – Mol Basis Dis 1832, 1866–1881.

Kousi M, Lehesjoki AE and Mole SE (2012) Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat 33, 42–63.

Kurze AK, Galliciotti G, Heine C, Mole SE, Quitsch A, et al. (2010) Pathogenic mutations cause rapid degradation of lysosomal storage disease-related membrane protein CLN6. Hum Mutat 31, E1163–1174.

Mole SE, Anderson G, Band HA, Berkovic SF, Cooper JD, et al. (2019) Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol 18, 107–116.

Mole SE, Michaux G, Codlin S, Wheeler RB, Sharp JD, et al. (2004) CLN6, which is associated with a lysosomal storage disease, is an endoplasmic reticulum protein. Exp Cell Res 298, 399–406.

Nelvagal HR, Lange J, Takahashi K, Tarczyluk-Wells MA and Cooper JD (2020) Pathomechanisms in the neuronal ceroid lipofuscinoses. Biochim Biophys Acta – Mol Basis Dis 1832, 1882–1893.

Sharp JD, Wheeler RB, Parker KA, Gardner RM, Williams RE, et al. (2003) Spectrum of CLN6 mutations in variant late-infantile neuronal ceroid lipofuscinoses. Hum Mutat 22, 35–42.

Sun G, Yao F, Tian Z, Ma T and Yang Z (2018) A first CLN6 variant case of late infantile neuronal ceroid lipofuscinoses caused by a homozygous mutation in a boy from China: A case report. BMC Med Genet 19, 177.

Teixeira CA, Espinola J, Hao L, Kohlschüttner J, Sawin DAP, et al. (2003) Novel mutations in the CLN6 gene causing a variant late infantile neuronal ceroid lipofuscinosis. Hum Mutat 21, 502–508.

Vicart P, Caron A, Guicheney P, Li Z, Prévost MC, et al. (1998) A missense mutation in the ub-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 20, 92–95.

Warrier V, Vieira M and Mole SE (2013) Genetic basis and phenotypic correlations of the neuronal ceroid lipofuscinoses. Biochim Biophys Acta – Mol Basis Dis 1832, 1827–1830.

Wheeler RB, Sharp JD, Schultz RA, Joslin JM, Williams RE, et al. (2002) The gene mutated in variant late-infantile neuronal ceroid lipofuscinoses (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein. Am J Hum Genet 70, 537–542.

Yamamoto S, Yamashita A, Arakaki N, Nemoto H and Yamazaki T (2012) Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. Hum Mutat 33, 42–63.

Yamashita A, Shiro Y, Hiraki Y, Yujiri T and Yamazaki T (2017) Identification of a CLN6-CLN8 complex recruits lysosomal enzymes at the ER for Golgi transfer. J Clin Invest 140, 4118–4132.

Yamashita A, Shiro Y, Hiraki Y, Yujiri T, and Yamazaki T (2020) Implications of graded reductions in CLN6’s anti-aggregate activity for the development of the neuronal ceroid lipofuscinoses. Biochim Biophys Res Commun 525, 883–888.
### Supporting Table 1  Primers used for the first step of constructing expression vectors

| Target  | Primer          | Sequence                                      |
|---------|-----------------|-----------------------------------------------|
| 132fsX  | 395-396delCT-Fwd | 5'-GGTGACTGTCACCCACCGGCTGCTC-3’              |
|         | 395-396delCT-Rev | 5'-CTGTCCGTGGAATTCTGCAGATATC-3’              |
| 173fsX  | 519delT-Fwd     | 5'-ATTATGAGAGTACCTGGTCCACTG-3’               |
|         | 519delT-Rev     | 5'-AGGTAATCCATAAGATGACAGA-3’                 |
| 239fsX  | 715-718delTTCG-Fwd | 5'-CACCTTCCCCTAGCTGGCCCTCGTCC-3’          |
|         | 715-718delTTCG-Rev | 5'-CAGCATGGAAGTGTAAGATGAAAGG-3’         |
| 243fsX  | 727delG-Fwd     | 5'-CATGCTGCCTCTCGTCCACGACGA-3’               |
|         | 727delG-Rev     | 5'-GACGGGCAAGATGGAAGG-3’                     |

### Supporting Table 2  Primers used for the second step of constructing expression vectors

| Target  | Sequence                                      |
|---------|-----------------------------------------------|
| 132fsX  | 5'-CTGTCCGTGGAATTCTGCAGATATC-3’              |
|         | 5'-GAATTCCAGCAGCAGGACAGGATGTC-3’             |
| 173fsX  | 5'-GAGAGCTTGGAATTCTGCAGATATC-3’              |
|         | 5'-GAATTCCAGTCCAGGAAAGGAGGGAAG-3’            |
| 239fsX  | 5'-TCGACACTGGAATTCTGCAGATATC-3’              |
|         | 5'-GAATTCCAGTCCAGGAAAGGAGGGAAG-3’            |
| 243fsX  | 5'-TCGACACTGGAATTCTGCAGATATC-3’              |
|         | 5'-GAATTCCAGTGGAAGGAGGGAAG-3’                |

### Supporting Table 3  The following primers sets are used in generating the CLN6 mutants

| Target  | Sequence                                      |
|---------|-----------------------------------------------|
| P299L   | 5'-CTGAGCAGCTCTGGGATTCTACACCCCT-3’            |
|         | 5'-TGGCCAGAGCGCTGGGACGATGAGA-3’               |
| 5A1     | 5'-GCAGACGCAGCAGCAGCTTTCTACACCCCTAC-3’       |
|         | 5'-GCTGCTGCTGCTGGACGATGAGCAGACCCCG-3’       |
| 5A2     | 5'-TGATGCTGCTGCTGGACGATGAGCAGACCCCG-3’       |
|         | 5'-TGGCCAGACGCAGCAGCTTTCTACACCCCTAC-3’       |
| 5A3     | 5'-TGATGCTGCTGCTGGACGATGAGCAGACCCCG-3’       |
|         | 5'-ATTCACAGCAGATGAGCAGACCCCGGGTACTTC-3’    |
| P297X   | 5'-TACGTCCTGTGGAATTCTGCAGATACCCCGCAG-3’    |
|         | 5'-ATTCACAGCAGATGAGCAGACCCCGGGTACTTC-3’    |
Supporting Fig. 1: Topological features shared by human and cat CLN6s. Boxed are transmembrane domains (TMs). Amino acids situated between the third (TM3) and the fourth (TM4) transmembrane domains correspond to the third loop.